Variability in prostate cancer detection among radiologists and urologists using MRI fusion biopsy.

Objectives: The aim of this study is to evaluate the impact of radiologist and urologist variability on detection of prostate cancer (PCa) and clinically significant prostate cancer (csPCa) with magnetic resonance imaging (MRI)-transrectal ultrasound (TRUS) fusion prostate biopsies.

Patients And Methods: The Prospective Loyola University MRI (PLUM) Prostate Biopsy Cohort (January 2015 to December 2020) was used to identify men receiving their first MRI and MRI/TRUS fusion biopsy for suspected PCa. Clinical, MRI and biopsy data were stratified by radiologist and urologist to evaluate variation in Prostate Imaging-Reporting and Data System (PI-RADS) grading, lesion number and cancer detection. Multivariable logistic regression (MVR) models and area under the curve (AUC) comparisons assessed the relative impact of individual radiologists and urologists.

Results: A total of 865 patients (469 biopsy-naïve) were included across 5 urologists and 10 radiologists. Radiologists varied with grading 15.4% to 44.8% of patients with MRI lesions as PI-RADS 3. PCa detection varied significantly by radiologist, from 34.5% to 66.7% ( = 0.003) for PCa and 17.2% to 50% ( = 0.001) for csPCa. Urologists' PCa diagnosis rates varied between 29.2% and 55.8% ( = 0.013) and between 24.6% and 39.8% ( = 0.36) for csPCa. After adjustment for case-mix on MVR, a fourfold to fivefold difference in PCa detection was observed between the highest-performing and lowest-performing radiologist (OR 0.22, 95%CI 0.10-0.47,  < 0.001). MVR demonstrated improved AUC for any PCa and csPCa detection when controlling for radiologist variation ( = 0.017 and  = 0.038), but controlling for urologist was not significant ( = 0.22 and  = 0.086). Any PCa detection (OR 1.64, 95%CI 1.06-2.55,  = 0.03) and csPCa detection (OR 1.57, 95%CI 1.00-2.48,  = 0.05) improved over time (2018-2020 vs. 2015-2017).

Conclusions: Variability among radiologists in PI-RADS grading is a key area for quality improvement significantly impacting the detection of PCa and csPCa. Variability for performance of MRI-TRUS fusion prostate biopsies exists by urologist but with less impact on overall detection of csPCa.